This conversation will focus on the NMIBC landscape and where CGON stacks up against competitors
This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Discussing the NMIBC landscape with a focus on CG Oncology's Cretostimogene Grenadenorepvec
Ticker(s): CGON, JNJ, TNREF, URGNWho's the expert?
Institution: Genesis Healthcare
- Board certified Urologist, Medical Director of Cancer Center, and Primary Investigator of the research division at Institution
- Treats 75 patients with NMIBC per year
- Clinical experience in general urology combined with specialized training in urologic surgical oncology, advanced endoscopic, laparoscopic and robotic surgery
Interview Goal
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
